These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 8074597)
1. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597 [TBL] [Abstract][Full Text] [Related]
2. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227 [TBL] [Abstract][Full Text] [Related]
3. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915 [TBL] [Abstract][Full Text] [Related]
4. [Pamidronate in the treatment of tumor-associated hypercalcemia]. Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492 [TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662 [TBL] [Abstract][Full Text] [Related]
6. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Jansson S; Tisell LE; Lindstedt G; Lundberg PA Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370 [TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism. Tal A; Graves L South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211 [TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851 [TBL] [Abstract][Full Text] [Related]
10. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. Nussbaum SR; Warrell RP; Rude R; Glusman J; Bilezikian JP; Stewart AF; Stepanavage M; Sacco JF; Averbuch SD; Gertz BJ J Clin Oncol; 1993 Aug; 11(8):1618-23. PubMed ID: 8336198 [TBL] [Abstract][Full Text] [Related]
11. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Wimalawansa SJ Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530 [TBL] [Abstract][Full Text] [Related]
12. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484 [TBL] [Abstract][Full Text] [Related]
13. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia. Sekine M; Takami H Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321 [TBL] [Abstract][Full Text] [Related]
14. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Sawyer N; Newstead C; Drummond A; Cunningham J Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289 [TBL] [Abstract][Full Text] [Related]
16. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy. Yates AJ; Murray RM; Jerums GJ; Martin TJ Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316 [TBL] [Abstract][Full Text] [Related]
17. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy. Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351 [TBL] [Abstract][Full Text] [Related]
18. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Dodwell DJ; Howell A; Morton AR; Daley-Yates PT; Hoggarth CR Postgrad Med J; 1992 Jun; 68(800):434-9. PubMed ID: 1437922 [TBL] [Abstract][Full Text] [Related]
19. An audit of the management of malignant hypercalcaemia. Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. Flores JF; Rude RK; Chapman RA; Belani CP; Chang AY; Pritchard JD; Hoff JV Cancer; 1994 May; 73(10):2527-34. PubMed ID: 8174049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]